What happened
The event date for this report is 2026-07-30. The Singapore-based Hilleman Laboratories announced it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. The account is based on one supplied report and should be read as a record of conditions known at that point, rather than as a statement about later developments. A health worker takes instructions on safe removal and disposal of used Personal Protective Equipment (PPE) at the 'Doffing' tent during a training by medical charity, Médecins Sans Frontières (MSF) to reinforce regional emergency response capacity for Ebola in the Democratic Republic of Congo (DRC) at Ongata Rongai, Kajiado County in Kenya on Jul 10, 2026.
The available figures and chronology
(File photo: AFP/Tony Karumba) PARIS: A Singapore-based organisation announced on Thursday (Jul 30) it was expected to develop an Ebola vaccine dubbed the "most promising" to fight back against a deadly outbreak in the Democratic Republic of Congo. Nearly 1,500 people have died in the conflict-wracked African country from the Bundibugyo strain of Ebola, for which there are no vaccines or treatments. These details help define the scale and immediate setting of the event without extending the evidence beyond what the supplied source states. Where a number is an estimate, provisional count, forecast or company claim, it should not be treated as a final independently audited total. The evidence packet does not support assumptions about motives, responsibility or longer-term outcomes beyond the facts described here.
The operational context
But there are several different efforts racing to develop a vaccine for the previously rare strain in the hope of stemming the escalating outbreak. World Health Organization experts have reported a single-dose shot based on the rVSV platform is the "most promising" candidate. These details help define the scale and immediate setting of the event without extending the evidence beyond what the supplied source states. Where a number is an estimate, provisional count, forecast or company claim, it should not be treated as a final independently audited total. The evidence packet does not support assumptions about motives, responsibility or longer-term outcomes beyond the facts described here.
What remained uncertain
This is because it uses the same platform as the only officially licensed Ebola vaccine Ervebo, which targets a different strain called Zaire. The Singapore-based Hilleman Laboratories announced on Thursday it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. These details help define the scale and immediate setting of the event without extending the evidence beyond what the supplied source states. Where a number is an estimate, provisional count, forecast or company claim, it should not be treated as a final independently audited total. The evidence packet does not support assumptions about motives, responsibility or longer-term outcomes beyond the facts described here.
The record at the time
Taken together, the supplied material supports the main development in the headline and the specific details above. It does not establish what happened after 2026-07-30, and no later outcome is inferred here. The report therefore preserves the event-date framing, attributes the account to the available evidence and avoids turning an early figure or stated plan into a settled result. Further official data, technical findings or independent reporting could refine the picture, but those materials were not part of this packet.
